The attached image shows microscope images of the engineered cells (nuclei in blue) with HIF-1 visualized (in red). In the left hand panel, cells are in hypoxia but no doxyxyclin is present, therefore HIF-1 remains active (red dots). In the right hand panel, the cells are grown in hypoxia and in the presence of doxyxyxlin, therefore the cyclic peptide inhibitor is produced and HIF-1 is inhibited, as demonstrated by the absence of the red dots. Credit: Image courtesy of University of Southampton
Researchers at the University of Southampton have engineered cells with a ‘built-in genetic circuit’ that produces a molecule that inhibits the ability of tumors to survive and grow in their low oxygen environment.The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of cancer cells. This results in the cancer cells being unable to survive in the low oxygen, low nutrient micro-environment.
As tumors develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cancer cells needing to adapt to low oxygen environment. To enable them to survive in hypoxic environments, tumors contain increased levels of protein Hypoxia-inducible factor 1 (HIF-1). HIF-1 senses reduced O2 levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels. It is thought that tumors primarily hijack the function of this protein (HIF-1) to survival and grow.
Professor Ali Tavassoli explains: “In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment…We’ve been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected.
“IThis opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer.” The genetic circuit is incorporated onto the chromosome of a human cell line, which encodes the protein machinery required for the production of their cyclic peptide HIF-1 inhibitor. The production of the HIF-1 inhibitor occurs in response to hypoxia in these cells. They demonstrated that even when produced directly in cells, this molecule still prevents the HIF-1 signalling and the associated adaptation to hypoxia.
The next step is to demonstrate the viability of this approach to the production and delivery of an anticancer molecule in a whole tumor model system. Professor Tavassoli adds: “The main application for this work is that it eliminates the need for the synthesis of our inhibitor, so that biologists conducting research into HIF function can easily access our molecule and hopefully discover more about the role of HIF-1 in cancer. This will also let us understand whether inhibiting HIF-1 function alone is enough to block cancer growth in relevant models. Another interesting aspect to the work is that it demonstrates the possibility of adding new machinery to human cells to enable them to make therapeutic agents in response to disease signals.” http://www.southampton.ac.uk/news/2016/11/built-in-circuit.page
Recent Comments